The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.
January 27th 2023
A team of experts from the United States and Canada performed this systematic review, considering for the first time patient values and preferences for their atopic dermatitis (AD) care.
Self-care for Atopic Dermatitis Potentially Feasible as Treatment Intervention
January 4th 2023With mixed findings from previous studies focused on atopic dermatitis and the use of cognitive behavioral therapy (CBT) as a treatment modality, investigators modified an existing online CBT intervention to account for the lack of clinical psychologists in the dermatological space.
Read More
Top 5 Most-Read Atopic Dermatitis Articles of 2022
December 27th 2022This year’s most-read articles on atopic dermatitis (AD) examined AD as a risk factor for other neurological and attention-deficit conditions and efforts to improve the detection of other comorbid conditions associated with the common skin condition.
Read More
Adjuvant Baricitinib, Topical Corticosteroids Show Long-term Efficacy in Moderate-to-Severe AD
December 22nd 2022Adult patients with moderate-to-severe atopic dermatitis (AD) in the phase 3 BREEZE-AD7 study showed sustained improvement of AD signs and symptoms after 68 weeks with combination treatment of bariticitinib and topical corticosteroids.
Read More
Greater Risk of Cataract Surgery Shown in Patients With Atopic Dermatitis, Allergic Diseases
December 16th 2022Korean patients with allergic diseases, including atopic dermatitis (AD), allergic rhinitis (AR), and asthma, had a higher risk of cataract surgery, and the combination of AD and AR resulted in the highest risk.
Read More
Childhood Maltreatment Associated With Atopic Disease
December 9th 2022Patients exposed to childhood maltreatment were at greater risk for developing atopic disease compared with unexposed counterparts, and risk of atopic dermatitis and allergic rhinoconjunctivitis may have been attentuated by misdiagnosis.
Read More
High Burden of AD, Bacterial Skin Infections Seen in Young Urban-Living Indigenous People
November 20th 2022Urban-living Indigenous children and young people in high-income countries reported a higher likelihood of current and severe symptoms of atopic dermatitis (AD) compared with a non-Indigenous population, as well as a higher incidence of bacterial skin infections.
Read More
Topical Calcineurin Inhibitors for AD Not Associated With Cancer
November 14th 2022Pimecrolimus and tacrolimus, 2 topical calcineurin inhibitors for the treatment of atopic dermatitis (AD), were not shown to increase the risk of cancer based on moderate-certainty evidence from a systematic review and meta-analysis.
Read More
Investigating Real-World Effectiveness of Disease-Modifying Therapies in AD by Skin Type
November 10th 2022Real-world patients with atopic dermatitis with dark skin types showed greater mean reduction in disease severity between baseline and 6 months with dupilumab compared with those with light skin types, whereas no differences were observed regarding severity reduction for methotrexate and ciclosporin.
Read More
Dupilumab Efficacy in AD Not Affected by Age of Disease Onset
October 25th 2022Dupilumab exhibited similarly significant and sustained improvements in atopic dermatitis (AD) signs, symptoms, and quality of life of adult patients with moderate to severe AD, regardless of age of disease onset, compared with placebo.
Read More
A digitally delivered targeted intervention of symptom and trigger education, treatment reminders, lifestyle coaching, and healthy lifestyle support demonstrated significant improvements in treatment adherence and related clinical outcomes among Icelandic patients with atopic dermatitis.
Read More
Skin Biomarkers Found to Predict Development of Pediatric Atopic Dermatitis
September 26th 2022Significant alterations were observed in lipid levels and other skin biomarkers for infants who developed atopic dermatitis (AD) vs controls, with phytosphingosine associated with the highest AD prediction accuracy.
Read More
Benefits of Dietary Elimination May Not Outweigh Risks in Atopic Dermatitis
August 23rd 2022Findings of a meta-analysis show that use of dietary elimination had a minimal effect on the severity of atopic dermatitis and may increase the risk of developing immunoglobulin E–mediated food allergy.
Read More
Drug Survival of Dupilumab Affected by Immunosuppressive Therapy, Older Age in AD
August 18th 2022Investigator Global Assessment score of very severe atopic dermatitis (AD) was associated with dupilumab discontinuation due to adverse effects, although generally adequate 1-, 2-, and 3-year drug survival rates were also observed.
Read More
Race, Insurance Type Among Predictors of Depressive Symptoms in Atopic Dermatitis
August 10th 2022Most patients with atopic dermatitis had flunctuating levels of depressive symptoms, with having public or no insurance, more severe itch, and skin pain cited as additional predictors of adverse mental health outcomes.
Read More
Overuse of Systemic Corticosteroids, Substantial Cost Burden for AD Seen in Germany
July 29th 2022Systemic corticosteroids were more commonly prescribed vs other systemic drug options in Germany for patients with atopic dermatitis (AD) despite their unfavorable risk-benefit profile, with a substantial economic burden cited among these populations.
Read More